Analytical Data
-
Gene name
IL23p19
- Application
-
Alternative Names
IL23p19；Interleukin-23 subunit alpha
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9NPF7
-
Expression Region
23-328aa
-
AA Sequence
IWELKKDVYV VELDWYPDAP GEMVVLTCDT PEEDGITWTL DQSSEVLGSG KTLTIQVKEF GDAGQYTCHK GGEVLSHSLL LLHKKEDGIW STDILKDQKE PKNKTFLRCE AKNYSGRFTC WWLTTISTDL TFSVKSSRGS SDPQGVTCGA ATLSAERVRG DNKEYEYSVE CQEDSACPAA EESLPIEVMV DAVHKLKYEN YTSSFFIRDI IKPDPPKNLQ LKPLKNSRQV EVSWEYPDTW STPHSYFSLT FCVQVQGKSK REKKDRVFTD KTSATVICRK NASISVRAQD RYYSSSWSEW ASVPCSGSTS GSGKPGSGEG STKGRAVPGG SSPAWTQCQQ LSQKLCTLAW SAHPLVGHMD LREEGDEETT NDVPHIQCGD GCDPQGLRDN SQFCLQRIHQ GLIFYEKLLG SDIFTGEPSL LPDSPVGQLH ASLLGLSQLL QPEGHHWETQ QIPSLSPSQP WQRLLLRFKI LRSLQAFVAV AARVFAHGAA TLSP
-
Molecular Weight
70 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
IL-23, an important cytokine in the immune response, is composed of two subunits: IL-23p19 and IL-23p40. The IL-23p19 subunit has gained significant attention in immunology and therapeutic research due to its pivotal role in the development and maintenance of inflammatory responses, particularly in autoimmune diseases, such as psoriasis, Crohn's disease, and rheumatoid arthritis. Elevated levels of IL-23 have been implicated in the pathogenesis of these conditions, as it promotes the differentiation and expansion of T-helper 17 (Th17) cells, which are crucial for mediating inflammation. Consequently, targeting IL-23 is a promising strategy for developing novel treatments. The production of recombinant IL-23p19 protein allows researchers to study its biological functions, investigate its interaction with receptors, and evaluate its potential as a therapeutic target. Understanding the structural and functional properties of IL-23p19 through recombinant techniques provides valuable insights into its role in immune regulation and the development of autoimmunity. This research is critical for advancing therapeutic approaches, including monoclonal antibodies and small molecule inhibitors, aimed at modulating IL-23 signaling pathways to alleviate the symptoms of chronic inflammatory diseases. Overall, the study of recombinant IL-23p19 protein is foundational for deciphering its contributions to immune pathology and the development of targeted immunotherapies.
